When was Valeritas founded?

Valeritas was founded in 2003 and raised its 1st funding round 5 years after it was founded.

Where is Valeritas located?

Valeritas is headquartered in Bridgewater, United States.

How many employees does Valeritas have?

As of Mar 01, 2026, the latest employee count at Valeritas is 51 - 200.

Is Valeritas a funded company?

Valeritas is a funded company, having raised a total of $231M across 6 funding rounds to date. The company's 1st funding round was a $***** Convertible Debt round, raised on Nov 10, 2008.

When was the latest funding round of Valeritas?

Valeritas' latest funding was a $***** Post IPO round on May 04, 2016, with participation from 2 investors. Its primary sector is Drug Delivery. In United States, the Drug Delivery sector has seen $245M in funding in 2026 to date.

Where does Valeritas rank among its competitors?

Valeritas ranks 10th amongst 97 active competitors, of which 32 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was CeQur, which secured $100M in Jun, 2026.

Who are the top competitors of Valeritas?

Valeritas' top competitors include scPharmaceuticals, CeQur and Vaxxas. Among them, CeQur secured the most recent funding round in June, 2026.

Valeritas - 2026 Company Profile, Funding & Competitors

Q: Is Valeritas an acquired company?

Valeritas got acquired by Zealand Pharma on Feb 10, 2020.

Company Details

Developer of wearable insulin patch pumps for insulin delivery through the skin. It offers holds one day's supply of fast-acting insulin and releases it at a continuous preset basal rate and on-demand bolus dosing at mealtimes. Its pump is not programmable and does not use electricity. Its devices are available at a preset basal rate to deliver diverse amounts of insulin in a day and on-demand bolus dosing.

Website: www.valeritas.com/
Social

Key Metrics

Founded Year

2003

Location

Bridgewater, United States

Stage

Acquired

Total Funding

$231M in 6 rounds

Latest Funding Round

Post IPO, May 04, 2016, $*****

Investors

Welsh, Carson, Anderson & Stowe & 13 more

Ranked

10^th among 97 active competitors

Employee Count

51 - 200 as on Mar 01, 2026

Similar Companies

scPharmaceuticals & 122 more

Exit Details

Acquired by Zealand Pharma (Feb 10, 2020)

View Valeritas' full profile

Valeritas got acquired by Zealand Pharma on Feb 10, 2020 at an acquisition amount of $*****.

Click here to take a look at Valeritas's acquisition in detail

Valeritas has raised a total funding of $231M over 6 rounds. Its first funding round was on Nov 10, 2008. Its latest funding round was a Post IPO round on May 04, 2016 for $*****. 2 investors participated in its latest round. Valeritas has 14 institutional investors.

Here is the list of recent funding rounds of Valeritas:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 04, 2016	1899990	Post IPO	9383150	9598468	7671925	1200896
Jul 07, 2014	3901879	Series D	2584296	1690569	9803529	9144142
Jun 04, 2013	9682311	Conventional Debt	5044029	5747052	5073037	CRG

Access funding benchmarks and valuations. Sign up today!

View details of Valeritas's funding rounds and investors

Valeritas' employee count trend

Valeritas has 51 - 200 employees as of Mar 26. Here is Valeritas's employee count trend over the years:

Uncover Valeritas' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Valeritas include scPharmaceuticals, CeQur and Vaxxas. Here is the list of Top 10 competitors of Valeritas, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	scPharmaceuticals 2013, Lexington (United States), Acquired	Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure	$78.7M	Orbimed, Sun Pharma & 4 others	59/100
2nd	CeQur 2008, Horw (Switzerland), Series E	Developer of wearable insulin delivery patch	$492M	Endeavour Vision, Schroders & 7 others	59/100
3rd	Vaxxas 2010, Brisbane (Australia), Series D	Developer of a needle-free patch technology for vaccine delivery applications	$91.2M	One Ventures, UniQuest & 12 others	59/100
4th	Hero Patch 2019, Boston (United States), Series A	Developer of antibodies or small molecules for drug delivery	$20.5M	Big Pi Ventures, Velocity Partners & 5 others	55/100
5th	Starton 2017, New York City (United States), Seed	Developer of drug delivery solution and drugs for treating oncology	$9.29M	LOVE Pharma, Goldfingr	52/100
6th	Scilex Holding 2019, Palo Alto (United States), Public	Developer of non-opioid therapies for acute and chronic pain	-	Frazier Life Sciences	52/100
7th	Corsair Phama 2014, San Francisco (United States), Series B	Developer of drugs for the treatemnt of cardiac diseases	$23M	New Rhein, Primavera & 3 others	52/100
8th	EoFlow 2011, Seongnam-si (South Korea), Acquired	Developer of a wearable disposable insulin patch for diabetes patients	-	Login Investment, LB Investment & 3 others	48/100
9th	AFYX Therapeutics 2013, Copenhagen (Denmark), Series A	Developer of drug patches for the treatment of mucosal diseases	$33.3M	Sofinnova Investments, Nordic Venture & 6 others	47/100
10th	Valeritas 2003, Bridgewater (United States), Acquired	Developer of wearable insulin patch pumps for insulin delivery through the skin	$231M	Abingworth, CRG & 12 others	46/100